Understanding the Chameleonic Breakthrough Cancer Pain.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
accepted:
07
01
2021
pubmed:
31
1
2021
medline:
13
10
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
Breakthrough cancer pain (BTcP) is a variegated phenomenon, that often presents in different ways in each individual, and may change its presentation in the same individual during the course of disease. An appropriate assessment is fundamental for depicting the pattern of BTcP in individuals. This information is determinant for a personalised management of BTcP. The use of opioids as needed, is recommended for the management of BTcP. There are several options which should be chosen according to the individual pattern of BTcP. In general, a drug with a short onset and offset should be preferred. Although oral opioids may still have specific indications, fentanyl products have been found to be more rapid and effective, providing analgesia in 5-15 min. The most controversial point regards the opioid dose to be used. The presence of tolerance suggests using a dose that is proportional to the dose used for background analgesia. In contrast, regulatory studies have suggested using the minimal available dose to be titrated until the effective dose. Further large studies should definitely settle this never-ending question.
Identifiants
pubmed: 33515376
doi: 10.1007/s40265-021-01466-5
pii: 10.1007/s40265-021-01466-5
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-418Références
van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51:1070–90.
Lemaire A, George B, Maindet C, Burnod A, Allano G, Minello C. Opening up disruptive ways of management in cancer pain: the concept of multimorphic pain. Support Care Cancer. 2019;27:3159–70.
pubmed: 31093768
Twycross RG. Relief of pain. In: Saunders C (ed) The management of terminal malignant disease. Edward Arnold, London, 1984, pp. 64–90.
Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.
pubmed: 11237376
pmcid: 2363790
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81.
pubmed: 1697056
Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157:2657–63.
pubmed: 27653423
Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manag. 2014;48:619–31.
Canal-Sotelo J, Trujillano-Cabello J, Larkin P, et al. Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm. BMC Palliat Care. 2018;17:81.
pubmed: 29807537
pmcid: 5971419
Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manag. 2010;40:183–90.
Mercadante S, Costanzo BV, Fusco F, Buttà V, Vitrano V. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manag. 2009;38:554–60.
Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28.
Mercadante S, Marchetti P, Cuomo A, et al. Factors influencing the clinical presentation of breakthrough pain in cancer patients. Cancers (Basel). 2018;10(6):E17520.
Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–34.
pubmed: 10353500
Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manag. 2014;47:57–76.
Løhre ET, Klepstad P, Bennett MI, et al. From “Breakthrough” to “Episodic” cancer pain? A European Association for palliative care research Network Expert Delphi survey toward a common terminology and classification of transient cancer pain exacerbations. J Pain Symptom Manag. 2016;51:1013–9.
Caraceni A, Martini C, Zecca E, et al. Working group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177–83.
Caraceni A, Bertetto O, Labianca R, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manag. 2012;43:833–41.
Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag. 2000; 20:87–92.
Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195–206.
pubmed: 15737812
Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15:9–18.
pubmed: 11212475
Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag. 2002;24:45–52.
Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28.
Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–5.
pubmed: 21215653
Mercadante S, Valle A, Porzio G, et al. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Curr Med Res Opin. 2013;29:667–71.
pubmed: 23551065
Mercadante S, Adile C, Torta R, et al. Meaningful cut-off pain intensity for breakthrough pain cahnges in advanced cancer patients. Curr Med Res Opin. 2013;29:93–7.
pubmed: 23198976
Mercadante S, Adile C, Giarratano A, Casuccio A. Breakthrough pain in patients with abdominal cancer pain. Clin J Pain. 2014;30:510–4.
pubmed: 24281289
Mercadante S, Caraceni A, Masedu F, Scipioni T, Aielli F. breakthrough cancer pain in patients receiving low doses of opioids for background pain. Oncologist. 2020;25:156–60.
pubmed: 31862860
Mercadante S, Masedu F, Valenti M, Aielli F. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study. Oral Oncol. 2019;95:87-90
Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2, management. Pharm Ther. 2005;30:354–61.
Haugen DF, Hjermstad MJ, Hagen N, Caraceni A. Kaasa S Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476–82.
pubmed: 20236762
Mercadante S, Lazzari M, Reale C, et al. Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. Clin J Pain. 2015;31:214–21.
pubmed: 25654429
Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag. 2004;28:505–10.
Ceyhan GO, Michalski CW, Demir IE, et al. Pancreatic pain. Best Pract Res Clin Gastroenterol. 2008;22:31–44.
pubmed: 18206811
Tanaka R, Ishikawa H, Sato T, Shino M, Omae K, Sato T, Osaka I. Safety profile of prophylactic rescue dosing of immediate-release oral opioids in cancer patients. J Pharm Health Care Sci. 2018;4:25.
pubmed: 30214820
pmcid: 6130058
Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–9.
pubmed: 20434717
Zeppetella G. Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care. 2009;18:331–7.
Currow DC, Clark K, Louw S, et al. A randomized, double-blind, crossover, dose ranging study to determine the optimal dose of oral opioid to treat breakthrough pain for patients with advanced cancer already established on regular opioids. Eur J Pain. 2020;24:983–91.
pubmed: 32060972
NICE. World Health Organization guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. ISBN: 978-92-4-155039-0
Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–iv191.
Azhar A, Kim YJ, Haider A, et al. Response to oral immediate-release opioids for breakthrough pain in patients with advanced cancer with adequately controlled background pain. Oncologist. 2019;24:125–31.
pubmed: 30254187
Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–90.
pubmed: 22233484
Cuomo A, Cascella M, Forte CA, et al. Careful breakthrough cancer pain treatment through rapid-onset transmucosal fentanyl improves the quality of life in cancer patients: results from the BEST multicenter study. J Clin Med. 2020;9:1003.
pmcid: 7230287
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.
pubmed: 18707904
Mercadante S, Adile C, Cuomo A, Aielli F, Marinangeli F, Casuccio A. The use of low doses of sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. Support Care Cancer. 2017;25:645–9.
pubmed: 27744534
Davies A, Vriens J, Kennett A, McTeggart. An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406–11.
Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007;96:1828–33.
pubmed: 17519902
pmcid: 2359971
Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin. 2009;25:2805–15.
pubmed: 19792837
Mercadante S, Prestia G, Adile C, Casuccio A. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain. 2014;15:602–7.
pubmed: 24561001
Mercadante S, Adile C, Masedu F, Marchetti P, Costanzi A, Aielli F. Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study. Eur J Pain. 2019;23:719–26.
pubmed: 30421474
Yen T-Y, Chiou JF, Chiang WY, et al. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study. Medicine. 2018;97:e11593.
pubmed: 30045291
pmcid: 6078661
Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Opin Res Opin. 2012;28:963–8.
Hagen NA, Fisher K, Victorino C. Farrar JT A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med. 2007;10:47–55.
pubmed: 17298253